<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE root>
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="research-article" dtd-version="1.2" xml:lang="en"><front><journal-meta><journal-id journal-id-type="publisher-id">Consilium Medicum</journal-id><journal-title-group><journal-title xml:lang="en">Consilium Medicum</journal-title><trans-title-group xml:lang="ru"><trans-title>Consilium Medicum</trans-title></trans-title-group><trans-title-group xml:lang="zh"><trans-title>Consilium Medicum</trans-title></trans-title-group></journal-title-group><issn publication-format="print">2075-1753</issn><issn publication-format="electronic">2542-2170</issn><publisher><publisher-name xml:lang="en">Consilium Medicum</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">705668</article-id><article-id pub-id-type="doi">10.26442/20751753.2026.4.203665</article-id><article-categories><subj-group subj-group-type="toc-heading" xml:lang="en"><subject>Articles</subject></subj-group><subj-group subj-group-type="toc-heading" xml:lang="ru"><subject>Статьи</subject></subj-group><subj-group subj-group-type="article-type"><subject>Research Article</subject></subj-group></article-categories><title-group><article-title xml:lang="en">Diagnosis of recurrent medullary thyroid cancer: Capabilities of PET/CT with <sup>18</sup>F-DOPA</article-title><trans-title-group xml:lang="ru"><trans-title>Диагностика рецидивов медуллярного рака щитовидной железы: возможности ПЭТ/КТ с <sup>18</sup>F-ДОФА</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-4045-1247</contrib-id><name-alternatives><name xml:lang="en"><surname>Ognerubov</surname><given-names>Nikolai A.</given-names></name><name xml:lang="ru"><surname>Огнерубов</surname><given-names>Николай Алексеевич</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>D. Sci. (Med.), D. Sci. (Jur.), Prof.</p></bio><bio xml:lang="ru"><p>д-р мед. наук, д-р юрид. наук, проф., проф. каф. онкологии и паллиативной медицины им. А.И. Савицкого, засл. работник высшей школы РФ, засл. врач РФ</p></bio><email>ognerubov_n.a@mail.ru</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0009-0007-8600-7586</contrib-id><name-alternatives><name xml:lang="en"><surname>Mirsalimova</surname><given-names>Olga O.</given-names></name><name xml:lang="ru"><surname>Мирсалимова</surname><given-names>Ольга Олеговна</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>MD, Radiol.</p></bio><bio xml:lang="ru"><p>врач-радиолог</p></bio><email>ognerubov_n.a@mail.ru</email><xref ref-type="aff" rid="aff2"/></contrib></contrib-group><aff-alternatives id="aff1"><aff><institution xml:lang="en">Russian Medical Academy of Continuous Professional Education</institution></aff><aff><institution xml:lang="ru">ФГБОУ ДПО «Российская медицинская академия непрерывного профессионального образования» Минздрава России</institution></aff></aff-alternatives><aff-alternatives id="aff2"><aff><institution xml:lang="en">Federal Network of Nuclear Medicine Centers PET-Technology</institution></aff><aff><institution xml:lang="ru">Федеральная сеть центров ядерной медицины «ПЭТ-Технолоджи»</institution></aff></aff-alternatives><pub-date date-type="pub" iso-8601-date="2026-05-31" publication-format="electronic"><day>31</day><month>05</month><year>2026</year></pub-date><volume>28</volume><issue>4</issue><issue-title xml:lang="en">Endocrinology</issue-title><issue-title xml:lang="ru">Эндокринология</issue-title><fpage>270</fpage><lpage>277</lpage><history><date date-type="received" iso-8601-date="2026-04-08"><day>08</day><month>04</month><year>2026</year></date><date date-type="accepted" iso-8601-date="2026-04-08"><day>08</day><month>04</month><year>2026</year></date></history><permissions><copyright-statement xml:lang="en">Copyright ©; 2026, Consilium Medicum</copyright-statement><copyright-statement xml:lang="ru">Copyright ©; 2026, ООО "Консилиум Медикум"</copyright-statement><copyright-year>2026</copyright-year><copyright-holder xml:lang="en">Consilium Medicum</copyright-holder><copyright-holder xml:lang="ru">ООО "Консилиум Медикум"</copyright-holder><ali:free_to_read xmlns:ali="http://www.niso.org/schemas/ali/1.0/"/><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/">https://creativecommons.org/licenses/by-nc-sa/4.0</ali:license_ref></license></permissions><self-uri xlink:href="https://consilium.orscience.ru/2075-1753/article/view/705668">https://consilium.orscience.ru/2075-1753/article/view/705668</self-uri><abstract xml:lang="en"><p><bold>Background.</bold> Medullary thyroid cancer (MTC) constitutes approximately 3–5% of all thyroid carcinomas and is characterized by a propensity for lymphogenic metastasis and frequent recurrences following surgical intervention. The use of combined positron emission tomography and X-ray computed tomography (PET/CT) with <sup>18</sup>F-dihydroxyphenylalanine (DOPA) has emerged as the most informative molecular imaging technique available. However, data elucidating the relationship between quantitative parameters of radiopharmaceutical agent (RPA) accumulation and the clinical and morphological characteristics associated with recurrence remain limited.</p> <p><bold>Aim. </bold>To assess the diagnostic efficacy of multiphase PET/CT utilizing <sup>18</sup>F-DOPA in detecting recurrences of MTC, to identify the optimal scanning time, and to perform a correlation analysis of maximum standardized uptake value (SUVmax) with various clinical parameters.</p> <p><bold>Materials and methods.</bold> This retrospective study included 12 patients with histologically confirmed MTC who underwent thyroidectomy with lymph node dissection. The representative sample consisted of 10 patients (5 females and 5 males) with established biochemical recurrence, with a mean age of 54 years. The PET/CT scans with <sup>18</sup>F-DOPA were performed on a GE Discovery PET/CT 710 scanner at 15, 30, and 60 minutes after RPA administration. Statistical analyses were conducted using IBM SPSS v.29.0.0 and MedCalc v.22.009.</p> <p><bold>Results.</bold> Local recurrence was identified in 9 patients, while metastases to regional lymph nodes were detected in 10 patients. The overall count of foci exhibiting pathological RPA accumulation was 30, including 16 foci in metastatic lymph nodes. Mean SUVmax values in metastatic lymph nodes were measured at 2.86, 3.49, and 2.78 at 15, 30, and 60 minutes, respectively. For local recurrences, the values were 2.54, 2.97, and 2.45 at the corresponding time points. The scanning mode established at the 30-minute mark was confirmed to be optimal. A significant direct correlation was identified between the latency period and SUVmax in the lymph nodes at the 30-minute interval. Receiver operating characteristic (ROC) analysis of SUVmax at 30 minutes revealed an area under the curve (AUC) of 0.833, indicating a sensitivity of 83.3% and a specificity of 80%.</p> <p><bold>Conclusions.</bold> PET/CT using <sup>18</sup>F-DOPA is demonstrated to be a highly effective method for the diagnosis of recurrent MTC. The optimal scanning time is 30 minutes after RPA administration. Furthermore, SUVmax at this time point has prognostic value for the aggressiveness of relapses and may facilitate stratification of patients into distinct risk groups.</p></abstract><trans-abstract xml:lang="ru"><p><bold>Обоснование.</bold> Медуллярный рак щитовидной железы (МРЩЖ) составляет 3–5% всех ее карцином и склонен к лимфогенному метастазированию и частым рецидивам после хирургического лечения. Гибридная позитронно-эмиссионная и компьютерная томография (ПЭТ/КТ) с <sup>18</sup>F-диоксифенилаланином (ДОФА) признана наиболее информативным методом молекулярной визуализации. Данные о взаимосвязи количественных параметров накопления радиофармпрепарата (РФП) с клинико-морфологическими характеристиками рецидива ограничены.</p> <p><bold>Цель.</bold> Оценить диагностическую эффективность мультифазной ПЭТ/КТ с <sup>18</sup>F-ДОФА в выявлении рецидивов МРЩЖ, определить оптимальное время сканирования и провести корреляционный анализ SUVmax с клиническими параметрами.</p> <p><bold>Материалы и методы.</bold> В ретроспективное исследование включены 12 пациентов с гистологически верифицированным МРЩЖ, перенесших тиреоидэктомию с лимфодиссекцией. Репрезентативная выборка составила 10 пациентов (5 женщин, 5 мужчин) с установленным биохимическим рецидивом, средний возраст – 54 года. ПЭТ/КТ с <sup>18</sup>F-ДОФА выполняли на сканере GE Discovery PET/CT 710 в режиме трех временных точек – 15, 30, 60 мин после введения РФП. Статистический анализ проведен с помощью IBM SPSS v.29.0.0 и MedCalc v.22.009.</p> <p><bold>Результаты.</bold> Местный рецидив диагностирован у 9 больных. Метастазы в регионарные лимфоузлы выявлены у 10 пациентов. Общее количество очагов с патологическим накоплением РФП – 30, среди которых метастазы в лимфоузлах различных уровней – 16. Средние значения SUVmax в метастатических лимфоузлах составили на 15, 30, 60-й минутах 2,86, 3,49, 2,78, а в зоне местного рецидива – 2,54, 2,97 и 2,45 соответственно. Оптимальный режим сканирования достоверно подтвержден на 30-й минуте. Установлена значимая прямая корреляция между длительностью латентного периода и SUVmax в лимфоузлах на 30-й минуте. ROC-анализ для SUVmax на 30-й минуте в прогнозировании раннего рецидива продемонстрировал AUC (площадь под кривой) 0,833, чувствительность 83,3% и специфичность 80%.</p> <p><bold>Заключение.</bold> ПЭТ/КТ с <sup>18</sup>F-ДОФА является высокоэффективным методом топической диагностики рецидивов МРЩЖ. Оптимальным временем сканирования является 30-я минута. SUVmax на 30-й минуте обладает прогностической значимостью в отношении агрессивности рецидива и может использоваться для распределения пациентов по группам риска.</p></trans-abstract><kwd-group xml:lang="en"><kwd>medullary thyroid carcinoma</kwd><kwd>lymphatic metastasis</kwd><kwd>local neoplasm recurrence</kwd><kwd>positron emission tomography/computed tomography</kwd><kwd>fluorodopa F18</kwd><kwd>prognostic value</kwd><kwd>standardized uptake value</kwd></kwd-group><kwd-group xml:lang="ru"><kwd>медуллярный рак щитовидной железы</kwd><kwd>метастазы в лимфоузлы</kwd><kwd>местный рецидив</kwd><kwd>гибридная позитронно-эмиссионная и компьютерная томография</kwd><kwd>18F-ДОФА</kwd><kwd>прогностическая значимость</kwd><kwd>SUVmax</kwd></kwd-group><funding-group/></article-meta></front><body></body><back><ref-list><ref id="B1"><label>1.</label><mixed-citation>Boucai L, Zafereo M, Cabanillas ME. Thyroid Cancer: A Review. JAMA. 2024;331(5):425-35. DOI:10.1001/jama.2023.26348</mixed-citation></ref><ref id="B2"><label>2.</label><mixed-citation>Chen J, Chen J, Zhang M, Hong Y. All-cause mortality in patients with medullary thyroid carcinoma of different ages: an inverse L-curve analysis study. Front Endocrinol (Lausanne). 2025;16:1574985. DOI:10.3389/fendo.2025.1574985</mixed-citation></ref><ref id="B3"><label>3.</label><mixed-citation>Jager EC, Brouwers AH, Metman MJH, et al. The value of (18)F-FDG PET/CT and (18)F-DOPA PET/CT in determining the initial surgical strategy of patients with medullary thyroid cancer: Preoperative PET/CT imaging for medullary thyroid cancer. Cancer Imaging. 2025;25(1):41. DOI:10.1186/s40644-025-00862-4</mixed-citation></ref><ref id="B4"><label>4.</label><mixed-citation>Muñoz de Nova JL, Valdés de Anca A, Torres Mínguez E, Martín-Pérez E. Narrative review of neck reinterventions for medullary thyroid carcinoma: indications and outcomes. Ann Thyroid. 2021;6:11-1. DOI:10.21037/aot-21-12</mixed-citation></ref><ref id="B5"><label>5.</label><mixed-citation>Oh MY, Jung KY, Choi H, et al. Distinct Impacts of Clinicopathological and Mutational Profiles on Long-Term Survival and Recurrence in Medullary Thyroid Carcinoma. Endocrinol Metab (Seoul). 2024;39(6):877-90. DOI:10.3803/EnM.2024.2027</mixed-citation></ref><ref id="B6"><label>6.</label><mixed-citation>Giovanella L, Treglia G, Iakovou I, et al. EANM practice guideline for PET/CT imaging in medullary thyroid carcinoma. Eur J Nucl Med Mol Imaging. 2020;47(1):61-77. DOI:10.1007/s00259-019-04458-6</mixed-citation></ref><ref id="B7"><label>7.</label><mixed-citation>Kjærulff MLG, Dias AH, Iversen P, et al. Early acquisition of [(18)F]FDOPA PET/CT imaging in patients with recurrent or residual medullary thyroid cancer is safe-and slightly better! Eur J Hybrid Imaging. 2022;6(1):20. DOI:10.1186/s41824-022-00140-7</mixed-citation></ref><ref id="B8"><label>8.</label><mixed-citation>Barollo S, Bertazza L, Watutantrige-Fernando S, et al. Overexpression of L-Type Amino Acid Transporter 1 (LAT1) and 2 (LAT2): Novel Markers of Neuroendocrine Tumors. PLoS One. 2016;11(5):e0156044. DOI:10.1371/journal.pone.0156044</mixed-citation></ref><ref id="B9"><label>9.</label><mixed-citation>Hoegerle S, Altehoefer C, Ghanem N, et al. 18F-DOPA positron emission tomography for tumour detection in patients with medullary thyroid carcinoma and elevated calcitonin levels. Eur J Nucl Med. 2001;28(1):64-71. DOI:10.1007/s002590000404</mixed-citation></ref><ref id="B10"><label>10.</label><mixed-citation>Treglia G, Cocciolillo F, Di Nardo F, et al. Detection rate of recurrent medullary thyroid carcinoma using fluorine-18 dihydroxyphenylalanine positron emission tomography: a meta-analysis. Acad Radiol. 2012;19(10):1290-9. DOI:10.1016/j.acra.2012.05.008</mixed-citation></ref><ref id="B11"><label>11.</label><mixed-citation>Fargette C, Imperiale A, Taïeb D. Molecular imaging of endocrine neoplasms with emphasis on 18F-DOPA PET: a practical approach for well-tailored imaging protocols. Q J Nucl Med Mol Imaging. 2022;66(2):141-7. DOI:10.23736/S1824-4785.22.03450-1</mixed-citation></ref><ref id="B12"><label>12.</label><mixed-citation>Taralli S, Lorusso M, Capotosti A, et al. Which Is the Optimal Scan Time of 18F-DOPA PET/CT in Patients With Recurrent Medullary Thyroid Carcinoma?: Results From a Dynamic Acquisition Study. Clin Nucl Med. 2020;45(3):e134-40. DOI:10.1097/RLU.0000000000002925</mixed-citation></ref><ref id="B13"><label>13.</label><mixed-citation>Zhang Z, Yu J, Rainer E, et al. The role of [18F]F-DOPA PET/CT in diagnostic and prognostic assessment of medullary thyroid cancer: a 15-year experience with 109 patients. Eur Thyroid J. 2024;13(4):e240089. DOI:10.1530/ETJ-24-0089</mixed-citation></ref><ref id="B14"><label>14.</label><mixed-citation>Laure Giraudet A, Al Ghulzan A, Aupérin A, et al. Progression of medullary thyroid carcinoma: assessment with calcitonin and carcinoembryonic antigen doubling times. Eur J Endocrinol. 2008;158(2):239-46. DOI:10.1530/EJE-07-0667</mixed-citation></ref><ref id="B15"><label>15.</label><mixed-citation>Центр Н.В., Рыжкова Д.В. Оптимизация протокола ПЭТ/КТ исследования с [18F]-ДОФА у пациентов с медуллярным раком щитовидной железы: проспективное исследование. Учёные записки ПСПбГМУ им. акад. И.П. Павлова. 2024;31(4):27-33 [Tsentr NV, Ryzhkova DV. Optimization of [18F]-DOPA PET/CT Protocol in Patients with Medullary Thyroid Carcinoma: a Prospective Study. The Scientific Notes of Pavlov University. 2024;31(4):27-33 (in Russian)]. DOI:10.24884/1607-4181-2024-31-4-27-33</mixed-citation></ref><ref id="B16"><label>16.</label><mixed-citation>Luster M, Karges W, Zeich K, et al. Clinical value of 18-fluorine-fluorodihydroxyphenylalanine positron emission tomography/computed tomography in the follow-up of medullary thyroid carcinoma. Thyroid. 2010;20(5):527-33. DOI:10.1089/thy.2009.0342</mixed-citation></ref><ref id="B17"><label>17.</label><mixed-citation>Archier A, Heimburger C, Guerin C, et al. (18)F-DOPA PET/CT in the diagnosis and localization of persistent medullary thyroid carcinoma. Eur J Nucl Med Mol Imaging. 2016;43(6):1027-33. DOI:10.1007/s00259-015-3227-y</mixed-citation></ref><ref id="B18"><label>18.</label><mixed-citation>Treglia G, Stefanelli A, Castaldi P, Rufini V. A standardized dual-phase 18F-DOPA PET/CT protocol in the detection of medullary thyroid cancer. Nucl Med Commun. 2013;34(2):185-6. DOI:10.1097/MNM.0b013e32835afb67</mixed-citation></ref><ref id="B19"><label>19.</label><mixed-citation>Soussan M, Nataf V, Kerrou K, et al. Added value of early 18F-FDOPA PET/CT acquisition time in medullary thyroid cancer. Nucl Med Commun. 2012;33(7):775-9. DOI:10.1097/MNM.0b013e3283543304</mixed-citation></ref><ref id="B20"><label>20.</label><mixed-citation>Golubić AT, Pasini Nemir E, Žuvić M, et al. The value of 18F-DOPA PET/CT in patients with medullary thyroid carcinoma and increased calcitonin values. Nucl Med Commun. 2017;38(7):636-41. DOI:10.1097/MNM.0000000000000696</mixed-citation></ref><ref id="B21"><label>21.</label><mixed-citation>Caobelli F, Chiaravalloti A, Evangelista L, et al. Predictive and prognostic value of 18F-DOPA PET/CT in patients affected by recurrent medullary carcinoma of the thyroid. Ann Nucl Med. 2018;32(1): 7-15. DOI:10.1007/s12149-017-1213-0</mixed-citation></ref><ref id="B22"><label>22.</label><mixed-citation>Koopmans KP, Neels ON, Kema IP, et al. Molecular imaging in neuroendocrine tumors: molecular uptake mechanisms and clinical results. Crit Rev Oncol Hematol. 2009;71(3):199-213. DOI:10.1016/j.critrevonc.2009.02.009</mixed-citation></ref><ref id="B23"><label>23.</label><mixed-citation>Santhanam P, Taïeb D. Role of (18) F-FDOPA PET/CT imaging in endocrinology. Clin Endocrinol (Oxf). 2014;81(6):789-98. DOI:10.1111/cen.12566</mixed-citation></ref><ref id="B24"><label>24.</label><mixed-citation>Yanagida O, Kanai Y, Chairoungdua A, et al. Human L-type amino acid transporter 1 (LAT1): characterization of function and expression in tumor cell lines. Biochim Biophys Acta. 2001;1514(2):291-302. DOI:10.1016/s0005-2736(01)00384-4</mixed-citation></ref><ref id="B25"><label>25.</label><mixed-citation>Lederer A, Kessler CJ, Bouzakri N, et al. The Pitfalls of Calcitonin as a Tumor Marker: Real-Life Data of Patients with Elevated Basal Calcitonin Levels but Without Evidence of Medullary Thyroid Carcinoma. JCM. 2026;15(7):2500. DOI:10.3390/jcm15072500</mixed-citation></ref><ref id="B26"><label>26.</label><mixed-citation>Ceolin L, Duval MADS, Benini AF, et al. Medullary thyroid carcinoma beyond surgery: advances, challenges, and perspectives. Endocr Relat Cancer. 2019;26(9):R499-518. DOI:10.1530/ERC-18-0574</mixed-citation></ref><ref id="B27"><label>27.</label><mixed-citation>Barbet J, Campion L, Kraeber-Bodéré F, et al. Prognostic impact of serum calcitonin and carcinoembryonic antigen doubling-times in patients with medullary thyroid carcinoma. J Clin Endocrinol Metab. 2005;90(11):6077-84. DOI:10.1210/jc.2005-0044</mixed-citation></ref><ref id="B28"><label>28.</label><mixed-citation>Soret M, Bacharach SL, Buvat I. Partial-volume effect in PET tumor imaging. J Nucl Med. 2007;48(6):932-45. DOI:10.2967/jnumed.106.035774</mixed-citation></ref></ref-list></back></article>
